The Lancet Haematology launched as a new journal within The Lancet group in 2014. Since that time, we have published over 250 research articles across an array of topics in classical haematology and haematology-oncology. We have been delighted to see papers published in the journal cited widely at conferences, be key pieces of evidence for regulatory approval of new drugs, and inform clinical…
Treatment with subcutaneous blinatumomab at the two dose regimens of 250 μg/500 μg and 500 μg/1000 μg resulted in promising preliminary activity and a manageable…
Treatment with subcutaneous blinatumomab at the two dose regimens of 250 μg/500 μg and 500 μg/1000 μg resulted in promising preliminary activity and a manageable…
The Lancet Haematology in conversation with · Episode
The Lancet Haematology in conversation with · Episode
Tremendous progress in treatment and outcomes has been achieved across the whole range of haematological malignancies in the past two decades. Several haematological malignancies are…
Tremendous progress in treatment and outcomes has been achieved across the whole range of haematological malignancies in the past two decades. Several haematological malignancies are…
Tremendous progress in treatment and outcomes has been achieved across the whole range of haematological malignancies in the past two decades. Several haematological malignancies are…
A woman in her fifties attended our institution for evaluation of epistaxis. She had a history of limited cutaneous systemic sclerosis that was diagnosed in…
